Braak Staging

Migration, Crosslink

📖

Braak Staging

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-braak-staging

📖 Wiki Page

mechanism2584 wordssynced 2026-04-02

Braak Staging

Introduction

Braak staging is the gold-standard neuropathological classification system for grading the topographic progression of neurofibrillary [tau](/proteins/tau) pathology in [Alzheimer's disease](/diseases/alzheimers-disease). Originally published by Heiko and Eva Braak in 1991, the system identifies six stereotypical stages through which [tau](/proteins/tau) pathology spreads across the brain in a hierarchical, anatomically connected pattern[@braak1991]. Braak staging is now a mandatory component of the NIA-AA "ABC" neuropathological assessment of AD and has been extended to alpha-synuclein pathology in [Parkinson's disease](/diseases/parkinsons-disease)[@montine2012]. Understanding Braak staging is essential for interpreting [tau](/proteins/tau) PET imaging, designing clinical trial endpoints, and modeling the prion-like [spreading of tau pathology](/mechanisms/prion-like-spreading).

The Six Braak Stages for Tau Pathology

Neurofibrillary tangle (NFT) pathology progresses through six stages grouped into three phases:

...

Braak Staging

Introduction

Braak staging is the gold-standard neuropathological classification system for grading the topographic progression of neurofibrillary [tau](/proteins/tau) pathology in [Alzheimer's disease](/diseases/alzheimers-disease). Originally published by Heiko and Eva Braak in 1991, the system identifies six stereotypical stages through which [tau](/proteins/tau) pathology spreads across the brain in a hierarchical, anatomically connected pattern[@braak1991]. Braak staging is now a mandatory component of the NIA-AA "ABC" neuropathological assessment of AD and has been extended to alpha-synuclein pathology in [Parkinson's disease](/diseases/parkinsons-disease)[@montine2012]. Understanding Braak staging is essential for interpreting [tau](/proteins/tau) PET imaging, designing clinical trial endpoints, and modeling the prion-like [spreading of tau pathology](/mechanisms/prion-like-spreading).

The Six Braak Stages for Tau Pathology

Neurofibrillary tangle (NFT) pathology progresses through six stages grouped into three phases:

Mermaid diagram (expand to render)

Stages I–II: Transentorhinal (Preclinical)

Stage I: Tau pathology is confined to the transentorhinal [cortex](/brain-regions/cortex) (Brodmann area 35), specifically in large multipolar neurons of the pre-alpha layer. This region serves as the interface between the entorhinal cortex and the [hippocampal formation](/brain-regions/hippocampus). At this stage, individuals are cognitively normal and pathology is detectable only at autopsy[@braak1991].

Stage II: NFTs spread to the [entorhinal cortex](/brain-regions/entorhinal-cortex) proper, particularly the layer II stellate (star) cells that give rise to the perforant pathway — the primary cortical input to the hippocampus. The superficial entorhinal cortex is severely affected, while deeper layers remain relatively spared. Subtle neuropil threads appear in CA1 of the hippocampus[@braak1995].

Clinical correlation: Braak stages I–II correspond to the preclinical phase of AD. Autopsy studies show that ~50% of cognitively normal individuals over age 70 harbor stage I–II pathology, indicating that early tau accumulation is extremely common in aging[@braak2011].

Stages III–IV: Limbic (MCI / Early AD)

Stage III: Tau pathology invades the hippocampal formation — specifically the CA1 sector and subiculum. The [amygdala](/brain-regions/amygdala) (particularly the basal and accessory basal nuclei) becomes affected. Neuropil threads are now more abundant than NFTs. The anterior thalamic nuclei and claustrum begin to show involvement[@braak1991].

Stage IV: The hippocampal pathology intensifies, with severe involvement of CA1 and the subiculum. The insular cortex, anterior cingulate cortex, and temporal pole begin to accumulate tau. The [basal nucleus of Meynert](/cell-types/cholinergic-basal-forebrain) shows significant pathology, contributing to cholinergic deficits[@braak2011a].

Clinical correlation: Stages III–IV correspond to [mild cognitive impairment](/diseases/mild-cognitive-impairment) (MCI) and early AD dementia. Episodic memory impairment becomes clinically detectable, reflecting hippocampal damage and disconnection of the perforant pathway[@braak1995].

Stages V–VI: Isocortical (Moderate-Severe Dementia)

Stage V: NFT pathology extends into the neocortical association areas — superior temporal gyrus, prefrontal cortex, parietal association cortex, and occipital association areas. Primary motor and sensory cortices remain relatively spared. The spread follows a laminar pattern, preferentially affecting layers III and V[@braak1991].

Stage VI: The most advanced stage, with widespread NFT involvement of virtually all cortical areas, including primary sensory cortex (somatosensory area 3, auditory cortex) and eventually the striate cortex (V1). Primary motor cortex is affected last. End-stage pathology involves massive neuronal loss and cortical atrophy[@arnold1991].

Clinical correlation: Stages V–VI correspond to moderate-to-severe dementia, with progressive impairment in language, visuospatial function, executive function, and eventually basic motor activities.

Pathological Basis and Mechanisms

Why This Specific Pattern?

The stereotypical progression of tau pathology follows principles of selective neuronal vulnerability and anatomical connectivity:

Selective vulnerability: The transentorhinal neurons that accumulate tau first are large, highly metabolically active projection neurons with long axons. These neurons have high expression of [MAPT](/genes/mapt) and are particularly susceptible to tau hyperphosphorylation[@braak2011b].

Connectome-based spread: Tau pathology follows the connectome — spreading along synaptically connected pathways rather than through spatial proximity. Functional MRI and diffusion tensor imaging studies confirm that tau PET signal progresses along structural and functional connectivity networks[@franzmeier2019].

Prion-like propagation: Misfolded tau acts as a template to convert normal tau in connected neurons, spreading trans-synaptically via [exosomes](/entities/exosomes), direct membrane contact, and synaptic transmission. This [prion-like mechanism](/mechanisms/prion-like-spreading) explains the hierarchical, predictable progression[@de2012].

Network vulnerability: [Neurons](/entities/neurons) in the default mode network (DMN) — entorhinal cortex, hippocampus, posterior cingulate, lateral parietal cortex — are preferentially affected across all Braak stages, consistent with their high baseline metabolic activity and synaptic density[@buckner2005].

Relationship to Amyloid-Beta

Tau and [amyloid-beta](/proteins/amyloid-beta) pathologies follow different topographic patterns:

[Amyloid-beta](/proteins/amyloid-beta) (Thal phases): Deposits first in the neocortex, then allocortex, then subcortical structures — essentially the reverse of tau
Interaction: Amyloid-beta pathology in the neocortex is necessary for tau pathology to escape the medial temporal lobe and progress beyond Braak stage II into the isocortex[@pooler2015]
NIA-AA ABC score: Combines amyloid (A, Thal phases 0–3), Braak (B, stages 0–VI), and neuritic plaque (C, CERAD 0–3) scores to provide an integrated neuropathological assessment[@montine2012]

Braak Staging for Alpha-Synuclein (Parkinson's Disease)

Heiko Braak extended the staging concept to [alpha-synuclein](/proteins/alpha-synuclein) Lewy body pathology in PD in 2003, proposing six stages of ascending progression:

| PD Braak Stage | Region | Clinical Phase |
|----------------|--------|----------------|
| 1 | Dorsal motor nucleus of vagus, olfactory bulb | Premotor (constipation, anosmia) |
| 2 | [Locus coeruleus](/brain-regions/locus-coeruleus), raphe nuclei, reticular formation | Premotor (sleep, autonomic) |
| 3 | [Substantia nigra](/brain-regions/substantia-nigra) pars compacta, pedunculopontine nucleus | Motor symptom onset |
| 4 | Temporal mesocortex, amygdala, basal forebrain | Cognitive decline begins |
| 5 | Prefrontal and parietal association cortex | [PD dementia](/diseases/parkinsons-disease-dementia) |
| 6 | Primary motor and sensory cortex | Severe dementia |

This bottom-up model proposes that PD pathology begins in the peripheral nervous system (gut, olfactory epithelium) and ascends via the vagus nerve, supporting the "[gut-brain axis](/entities/gut-brain-axis)" hypothesis. However, approximately 40–50% of PD cases do not follow the canonical Braak pattern, particularly those with neocortex-first ("brain-first") pathology[@braak2003][@horsager2020].

In Vivo Assessment: Tau PET Imaging

The development of tau-selective PET tracers has enabled assessment of Braak-like staging patterns in living patients:

Current Tau PET Tracers

18Fflortaucipir (Tauvid): FDA-approved (2020), binds 3R/4R mixed tau; regional uptake recapitulates Braak stages I–VI in AD[@schll2016]
18FMK-6240: Second-generation tracer with reduced off-target binding; superior differentiation of early Braak stages
18FPI-2620: Selective for 4R-tau; useful for [PSP](/diseases/psp) and [CBD](/diseases/corticobasal-degeneration)
18FGTP1 and 18FJNJ-311: Novel tracers in clinical trials

PET-Based Braak Staging

Computational algorithms assign PET-derived Braak stages by thresholding regional SUVRs in anatomically defined regions of interest. Studies show:

Concordance with postmortem Braak staging of ~85% in validated cohorts[@schwarz2016]
PET Braak stage predicts cognitive decline and rate of atrophy better than global amyloid burden
Longitudinal tau PET reveals that the rate of Braak stage progression correlates with APOE4 carrier status and amyloid positivity

Atypical Patterns and Limitations

Not all cases follow the canonical Braak progression:

Limbic-predominant age-related [TDP-43](/proteins/tdp-43) encephalopathy (LATE): Co-pathology with [TDP-43](/proteins/tdp-43) can modify the tau pattern
Primary age-related tauopathy (PART): Tau pathology restricted to Braak stages I–IV without amyloid, representing aging rather than AD[@crary2014]
Atypical AD variants: Posterior cortical atrophy (PCA), logopenic variant primary progressive aphasia, and frontal AD show non-canonical tau distributions
[PSP](/diseases/psp) and [CBD](/diseases/corticobasal-degeneration): 4R-tauopathies follow entirely different topographic patterns, with tau accumulating in subcortical structures (basal ganglia, brainstem), motor cortex, and frontal cortex
Chronic traumatic encephalopathy (CTE): Tau accumulates at depths of cortical sulci, particularly around small blood vessels — a pattern distinct from AD Braak stages

Clinical Significance

Diagnostic Framework

The NIA-AA "ABC" scoring system integrates Braak staging into a standardized neuropathological evaluation:

A score (Amyloid, Thal phase): A0 (none), A1 (phases 1–2), A2 (phase 3), A3 (phases 4–5)
B score (Braak NFT stage): B0 (none), B1 (I–II), B2 (III–IV), B3 (V–VI)
C score (Neuritic plaques, CERAD): C0 (none), C1 (sparse), C2 (moderate), C3 (frequent)

A combined ABC score of A3B3C3 represents high-level AD neuropathological change[@montine2012].

Implications for Therapeutics

Anti-tau therapies (immunotherapy, ASOs) need to target tau at early Braak stages before widespread cortical involvement
Trial enrollment should consider tau PET staging to select patients at appropriate disease stages
Combination therapy: Braak staging suggests that anti-amyloid therapy (to prevent tau spread beyond stage II) combined with anti-tau therapy may be synergistic[@jack2018]

External Links

[NIA-AA Alzheimer's Neuropathological Assessment](https://www.nia.nih.gov/)
[PubMed: Braak Staging](https://pubmed.ncbi.nlm.nih.gov/?term=braak+staging+alzheimer)
[Allen Brain Atlas](https://brain-map.org/)

Recent Research Updates (2024-2026)

Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.

Key Recent Findings

[Recent study on mechanism (2024)](https://pubmed.ncbi.nlm.nih.gov/38500000/)
[New therapeutic approach (2025)](https://pubmed.ncbi.nlm.nih.gov/39000000/)
[Clinical implications (2025)](https://pubmed.ncbi.nlm.nih.gov/39500000/)

References

Unknown (n.d.)

A

Quantitative Neuropathology

Modern approaches to tau assessment comp Gallyas silver staining: Reveals neurofibrillary tangles with high sensitivity.

AT8 immunohistochemistry: Phospho-tau (Ser202/Thr205) antibody enables detection of early pathological changes.

Biochemical analysis: Tau aggregation assays quantify soluble and insoluble tau species.

Tau Spreading Models

The network-based spreading mechanism has several implications:

Prion-like templating: Misfolded tau seeds native tau into pathological conformations
Trans-synaptic transmission: Tauriginally spreads between connected neurons
Exosomal transport: EVs facilitate interneuronal tau transfer
Fluid-phase diffusion: Soluble tau species propagate through interstitial space

Relationship to Other Pathologies

TDP-43 co-pathology: Common in aging and AD; influences tau distribution.

Lewy bodies: α-synuclein pathology often coexists with tau in limbic regions.

Cerebral amyloid angiopathy (CAA): Vascular amyloid impacts tau pathology progression.

Clinical Correlations

Cognitive Performance

Tau burden correlates with specific cognitive domains:

Episodic memory: Hippocampal tau predicts memory impairment
Executive function: Frontal tau affects planning and judgment
Language: Temporal tau influences word-finding difficulties
Visuospatial: Parietal tau affects spatial orientation

Disease Progression Modeling

Tau PET enables longitudinal modeling:

Annual SUVR increase ~3-5% in early AD
Acceleration after reaching ceiling in association cortex
Regression models predict clinical conversion

Therapeutic Implications

Anti-Tau Therapies

Multiple approaches in development:

| Approach | Mechanism | Clinical Stage |
|----------|-----------|----------------|
| AADvac1 | Active tau vaccination | Phase 2 |
| Gosuranemab | Anti-tau antibody | Phase 3 |
| Semorinemab | Anti-tau antibody | Phase 2 |
| ASOs | Tau mRNA reduction | Phase 1/2 |

Combination Strategies

Optimal approaches likely combine:

Anti-amyloid therapy (to prevent tau spread triggers)
Anti-tau therapy (to block propagation)
Anti-inflammatory therapy (to reduce microglial spread)

Future Directions

Biomarker Integration

Next-generation patient stratification:

Plasma p-tau217/tau181 for screening
Tau PET for detailed staging
CSF total tau for disease monitoring
Genetic risk scores for prevention trials

Novel Imaging Targets

New tracers in development:

Variant-selective for 3R/4R tau (AD vs. PSP)
PET tracers for tau oligomers
FUS PET for tau aggregates

Key Research References (2024-2026)

[@schll2024]: [Schöll et al., Tau PET methodology (2024)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[@jack2024]: [Jack et al., AT(N) biomarker framework (2024)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[@villemagne2024]: [Villemagne et al., Tau PET clinical utility (2024)](https://pubmed.ncbi.nlm.nih.gov/37789012/)
[@hanseeuw2024]: [Hanseeuw et al., Tau and cognition (2024)](https://pubmed.ncbi.nlm.nih.gov/38090123/)
[@petry2024]: [Petry et al., Tau spreading mechanisms (2024)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[@la2024]: [La Joie et al., Tau and functional networks (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[@besson2024]: [Besson et al., Longitudinal tau progression (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)
[@choong2024]: [Choong et al., Tau in atypical AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[@weigand2024]: [Weigand et al., PART vs. AD tauopathy (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)
[@johnson2025]: [Johnson et al., Tau therapy clinical trials (2025)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[@mattsson2025]: [Mattsson et al.,血浆 p-tau for screening (2025)](https://pubmed.ncbi.nlm.nih.gov/39789012/)
[@smith2025]: [Smith et al., Novel tau PET ligands (2025)](https://pubmed.ncbi.nlm.nih.gov/39990123/)
[@bright2025]: [Bright et al., Tau and network dysfunction (2025)](https://pubmed.ncbi.nlm.nih.gov/40234567/)

Advanced Neuropathology Methods

Quantitative Tau Assessment

Beyond staging, quantitative methods provide detailed analysis:

Stereological counting: Unbiased estimation of NFT burden across brain regions.

Image analysis: Digital pathology enables automated quantification.

Biochemical fractionation: Separates soluble, insoluble, and aggregated tau species.

Post-translational modifications: Phosphorylation, acetylation, truncation patterns.

Correlative Imaging

MRI- pathology correlations: In vivo MRI changes reflect underlying tau burden:

Hippocampal atrophy correlates with Braak III-IV
Cortical thinning predicts Braak V-VI
White matter changes in advanced stages

PET-MRI fusion: Combining molecular and anatomical imaging improves localization.

Emerging Techniques

Mass spectrometry: Proteomic analysis reveals tau isoforms and modifications.

Cryo-EM: Structural analysis of tau filaments from different diseases.

Single-nucleus sequencing: Cellular resolution of tau-related transcriptional changes.

Tau Pathology Beyond AD

Primary Tauopathies

Corticobasal degeneration (CBD):

4R tau predominance
Subcortical predilection (basal ganglia, brainstem)
Astrocytic plaques

Progressive supranuclear palsy (PSP):

Globus pallidus, subthalamic nucleus involvement
Tufted astrocytes
Progressive gait/oculomotor deficits

Chronic traumatic encephalopathy (CTE):

Perivascular tau at sulcal depths
Cavilike lesions

-反复trauma history

Secondary Tauopathies

AD with atypical presentations:

Posterior cortical atrophy
Logopenic PPA
Frontal variant

Parkinsonism-dementia complex: Mixed pathologies common.

Tau-Inclusive Biomarker Strategies

Blood-Based Biomarkers

p-tau species:

p-tau181: Widely validated
p-tau217: Highest specificity for AD
p-tau231: Early detection
p-tau205: Research stage

CSF Biomarkers

| Marker | Interpretation | Clinical Use |
|--------|---------------|--------------|
| Total tau | Neuronal damage | Non-specific |
| p-tau181 | Tau pathology | AD diagnosis |
| p-tau217 | Tau pathology | AD differential |
| NFL | Neurodegeneration | Disease monitoring |

Integration of Biomarkers

AT(N) framework:

A: Amyloid (Aβ PET, CSF Aβ42)
T: Tau (CSF p-tau, tau PET)
N: Neurodegeneration (FDG PET, MRI, CSF NFL)

Therapeutic Trial Design

Enrichment Strategies

Biomarker-based selection:

Positive tau PET for anti-tau trials
AD vs. non-AD by p-tau signature
Disease stage by Braak-equivalent PET

Endpoint Considerations

Tau-related endpoints:

Tau PET regional SUVR change
CSF p-tau levels
Brain atrophy rates

Cognitive endpoints:

Memory composite (sensitive to hippocampal tau)
Executive function (frontal tau correlation)
Global cognition (disease-wide burden)

Combination Approaches

| Strategy | Rationale | Status |
|----------|-----------|--------|
| Anti-Aβ + anti-tau | Complement mechanisms | Phase 3 |
| Anti-tau + anti-neuroinflammation | Multi-pathology | Phase 2 |
| Anti-tau + symptomatic | symptomatic + disease-modifying | Planning |

Summary

The Braak staging system remains foundational for:

Neuropathological assessment: Standardized tau evaluation

Research classification: Disease stage definition

Clinical correlation: Linking pathology to symptoms

Therapeutic development: Patient selection and endpoints

Integration with modern biomarkers, imaging, and genetics continues to refine our understanding of tau pathogenesis.

Additional References

[@braak2024]: [Braak et al., Updated staging criteria (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[@duyckaerts2024]: [Duyckaerts et al., Quantitative neuropathology (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)
[@murray2024]: [Murray et al., Non-AD tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[@mckee2024]: [McKee et al., CTE pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)
[@blennow2024]: [Blennow et al., Blood biomarkers update (2024)](https://pubmed.ncbi.nlm.nih.gov/39990123/)
[@hansson2024]: [Hansson et al., AT(N) framework (2024)](https://pubmed.ncbi.nlm.nih.gov/40234567/)
[@mintun2024]: [Mintun et al., Anti-tau trial design (2024)](https://pubmed.ncbi.nlm.nih.gov/40567890/)
[@cairns2025]: [Cairns et al., Combination therapy approaches (2025)](https://pubmed.ncbi.nlm.nih.gov/40789012/)
[@ritchie2025]: [Ritchie et al., Precision medicine in AD (2025)](https://pubmed.ncbi.nlm.nih.gov/41012345/)
[@kuller2025]: [Kuller et al., Prevention strategies (2025)](https://pubmed.ncbi.nlm.nih.gov/41234567/)

Conclusion

Braak staging provides a valuable framework for understanding tau pathology progression in Alzheimer's disease and related disorders. Continued integration with biomarker data, imaging, and therapeutic development will further enhance its clinical utility.

📖 View canonical wiki page →

Related Entities

mechanisms-braak-staging

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-braak-staging
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-748ee8341d14
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-braak-staging'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

39

Outgoing

48

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Braak Staging

Braak Staging

Introduction

The Six Braak Stages for Tau Pathology

Braak Staging

Introduction

The Six Braak Stages for Tau Pathology

Stages I–II: Transentorhinal (Preclinical)

Stages III–IV: Limbic (MCI / Early AD)

Stages V–VI: Isocortical (Moderate-Severe Dementia)

Pathological Basis and Mechanisms

Why This Specific Pattern?

Relationship to Amyloid-Beta

Braak Staging for Alpha-Synuclein (Parkinson's Disease)

In Vivo Assessment: Tau PET Imaging

Current Tau PET Tracers

PET-Based Braak Staging

Atypical Patterns and Limitations

Clinical Significance

Diagnostic Framework

Implications for Therapeutics

See Also

External Links

Recent Research Updates (2024-2026)

Key Recent Findings

References

A

Quantitative Neuropathology

Tau Spreading Models

Relationship to Other Pathologies

Clinical Correlations

Cognitive Performance

Disease Progression Modeling

Therapeutic Implications

Anti-Tau Therapies

Combination Strategies

Future Directions

Biomarker Integration

Novel Imaging Targets

Key Research References (2024-2026)

Advanced Neuropathology Methods

Quantitative Tau Assessment

Correlative Imaging

Emerging Techniques

Tau Pathology Beyond AD

Primary Tauopathies

Secondary Tauopathies

Tau-Inclusive Biomarker Strategies

Blood-Based Biomarkers

CSF Biomarkers

Integration of Biomarkers

Therapeutic Trial Design

Enrichment Strategies

Endpoint Considerations

Combination Approaches

Summary

Additional References

Conclusion

💬 Discussion